Clinical Trials

Study Title:
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers

For more information about the trial above please contact the study team:

Principal Investigator, Scott Lindhorst, at lindhors@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina